Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 06:01 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Avatrombopag for the Treatment of Thrombocytopenia in Adults Scheduled for a Surgical Procedure
NCT03326843 · Sobi, Inc. · PHASE3 · terminated · last registry update 2020-04-15 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Study was terminated due to enrollment challenges.” | – | Registry record, Sobi, Inc. |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against MPL within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2021-03-18Also stopped (terminated): Shionogi, Placebo + Lusutrombopag (NCT01054443)
- 2021-02-26Results posted on the registry: Shionogi, Lusutrombopag (NCT01129024)
- 2021-02-26Also stopped (terminated): Shionogi, Lusutrombopag (NCT01129024)
- 2021-02-24Results posted on the registry: Shionogi, Placebo + Lusutrombopag (NCT01054443)
- 2021-02-15Results posted on the registry: Kyowa Kirin Korea Co., Ltd., AMG531 (NCT02094417)
- 2021-02-08Also stopped (terminated): Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH, Standard chemotherapy + Romiplostim (NCT03622931)
- 2021-01-28Phase 3 first posted: Peking Union Medical College Hospital, Avatrombopag 20 MG (NCT04728789)
- 2020-12-08Also stopped (withdrawn): Memorial Sloan Kettering Cancer Center, Avatrombopag (NCT04437953)
- 2020-11-24Results posted on the registry: Case Comprehensive Cancer Center, eltrombopag olamine (NCT02071901)
- 2020-11-03Also stopped (terminated): PrECOG, LLC., Phase I- Cytarabine & Eltrombopag + Phase II- Sequence A (NCT01656252)
- 2020-08-18Phase 3 first posted: Sobi, Inc., Avatrombopag + Placebo (NCT04516967)
- 2020-06-05Results posted on the registry: National Heart, Lung, and Blood Institute (NHLBI), Cohort 1: hATG, CsA, EPAG Day 14 to Month 6 + Cohort 2: hATG, CsA, EPAG Day 14 to Month 3 (NCT01623167)
- 2020-02-18Results posted on the registry: M.D. Anderson Cancer Center, Eltrombopag + Hypomethylating Agent (HMA) (NCT01893372)
- 2020-01-21Results posted on the registry: Kyowa Kirin Co., Ltd., AMG 531 (NCT00440037)
- 2020-01-10Results posted on the registry: Amgen, Romiplostim + Placebo (NCT00111475)
- 2020-01-02Results posted on the registry: M.D. Anderson Cancer Center, Eltrombopag + Decitabine (NCT02010645)
- 2020-01-02Also stopped (terminated): M.D. Anderson Cancer Center, Eltrombopag + Decitabine (NCT02010645)
- 2019-12-20Results posted on the registry: Amgen, Romiplostim (NCT00117143)
- 2019-11-25Also stopped (withdrawn): University of Cincinnati, Eltrombopag (NCT01194167)
- 2019-11-13Also stopped (terminated): University of Texas Southwestern Medical Center, Eltrombopag (NCT01821625)
- 2019-10-22Results posted on the registry: University of Texas Southwestern Medical Center, Eltrombopag (NCT01821625)
- 2019-09-19Phase 3 first posted: Kyowa Kirin Co., Ltd., Romiplostim (NCT04095936)
- 2019-08-28Results posted on the registry: Amgen, Romiplostim (NCT02279173)
- 2019-08-22Results posted on the registry: National Heart, Lung, and Blood Institute (NHLBI), Eltrombopag (NCT00961064)
- 2019-07-30Results posted on the registry: M.D. Anderson Cancer Center, Eltrombopag + Placebo (NCT01000051)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision